WO2004029049A1 - 2-アシルアミノチアゾール誘導体の新規な塩 - Google Patents
2-アシルアミノチアゾール誘導体の新規な塩 Download PDFInfo
- Publication number
- WO2004029049A1 WO2004029049A1 PCT/JP2003/012419 JP0312419W WO2004029049A1 WO 2004029049 A1 WO2004029049 A1 WO 2004029049A1 JP 0312419 W JP0312419 W JP 0312419W WO 2004029049 A1 WO2004029049 A1 WO 2004029049A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- reaction
- patent document
- acid
- present
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Definitions
- the present invention relates to 1- (3-chloro-5- ⁇ [4- (4-chlorothiophen-2-yl) -5- (4-cyclohexyl) useful as a medicament, particularly as a therapeutic agent for thrombocytopenia.
- compound A (Hereinafter referred to as “compound A”.)
- the present invention relates to a medicine comprising the compound A as an active ingredient.
- Platelets are nonnucleated blood cells that play a major role in physiological hemostasis and pathological thrombus formation, and in vivo, platelets are constantly produced by megakaryocytes, precursor cells. Platelet production is derived from pluripotent stem cells, like other blood cells, and pluripotent stem cells become megakaryocyte progenitors and then into megakaryoblasts, prokaryotes, and megakaryocytes. In the process of megakaryocyte maturation, immature megakaryocytes become polyploid by performing only DNA synthesis without cell division. After that, cytoplasmic maturation begins, a platelet separation membrane is formed, the cytoplasm is ruptured, and platelets are released. '
- thrombocytopenia causes severe symptoms such as bleeding tendency.
- platelet transfusion the most effective means of thrombocytopenia treatment is platelet transfusion, but thrombocytopenia is not available because there is no sufficient platelet supply and the life of the transferred platelets is short. It is difficult to improve the situation sufficiently.
- platelet transfusions include viral infection, production and transfer of alloantibodies.
- GVHD Graft Versus Host Disease
- TPO c-Mpl ligand tocopodium nbopoetin
- Non-patent Document 2 a modification of the 163rd amino acid from the N-terminus of TPO with polyethylene glycol
- Patent Document 1 benzodiazepine derivatives
- Patent Document 2 acylhydrazone derivatives
- Patent Document 3 diazonaphthalene derivatives
- Patent Document 4 pyrrolocarbazole derivatives
- Patent Document 5 pyrrolophenanthridine derivatives.
- Patent Document 5 pyrrolophthalimide derivatives
- Patent Document 7 It is known that the compound represented by the following general formula (I) has a platelet-increasing effect (Patent Document 7).
- Patent Document 7 describes a compound containing thiazole which may be substituted as X 1 and -NHCO- as Y 1 .
- the compound of the present invention does not have an A 1 group in the literature such as a thiazolyl group.
- Patent Document 8 It is also known that the compound represented by the following general formula (II) has a platelet-increasing effect.
- Patent Document 8 describes a thiazole which may be substituted as X 1 and a compound containing —NHCO— as Y 1 .
- the compound of the present invention does not have the W 1 group in the literature.
- the literature there is no specific disclosure of the compound in which the nitrogen atom is directly substituted at the 5-position of the thiazole in the Examples and the like.
- Patent Document 9 It is known that a compound represented by the following general formula (III) has a platelet-increasing effect (Patent Document 9).
- Patent Document 9 discloses an aryl or pyridyl compound in which R 1 may be substituted, but does not disclose a substituted phenyl compound such as the compound of the present invention.
- Ar may have a substituent.
- a pyridyl compound having a substituted pyridin ring as a substituent as in the present invention is not disclosed.
- Non-Patent Document 10 a compound having a cholecystokine and gastrin receptor antagonistic action
- Non-Patent Document 4 an anti-inflammatory property Compounds
- Non-Patent Document 1 Nature, 1994, Vol. 369, ⁇ ⁇ 568-571
- Non-Patent Document 2 Blood, 2001, Vol. 98, p.3241-3248
- Non-Patent Document 3 Blood, 2002, Vol. 99, p.2599-2602
- Non-Patent Document 4 Chemical and Pharmaceutical Bulletin, 1977, Vol. 25, No. 9, p.2292-2299
- Patent Document 1 Japanese Patent Application Laid-Open No. 11-152276
- Patent Document 2 International Publication No. 99 / 1U6 2 pamphlet
- Patent Document 3 WO 00/35446 pamphlet
- Patent Document 5 JP-A-10-212289
- Patent Document 7 WO 01/07 4 23 pamphlet
- Patent Document 8 WO 01/053267 pamphlet
- Patent Document 9 International Publication No. 02/062775 pamphlet
- Patent Document 10 Japanese Patent No. 3199451 Disclosure of the invention
- the present inventors have conducted intensive studies on compounds having a thrombocytosis effect and found that a novel salt of a 2-acylaminothiazole derivative, that is, compound A, has an excellent thrombocytosis effect, and completed the present invention. It was made.
- 'Compound A which is the compound of the present invention, has the following chemical structure.
- a compound A useful as a platelet polypharmaceutical and a medicament containing the compound A as an active ingredient, particularly a thrombocytosis agent and a therapeutic agent for Z or thrombocytopenia.
- the compound of the present invention may form a hydrate and Z or a solvate, and these compounds are also included in the present invention.
- the compound of the present invention can be produced by applying various known synthetic methods utilizing characteristics based on the basic skeleton or the type of the substituent. The following is a typical production method. In some cases, each step may be performed in a different order. Depending on the type of the functional group, it may be effective in production technology to replace the functional group with an appropriate protecting group at the raw material or intermediate stage, that is, a group that can be easily converted to the functional group. is there. Thereafter, the desired compound can be obtained by removing the protecting group as necessary.
- Such functional groups include, for example, carbonyl groups and amino groups. Examples of such protecting groups are "Protective Groups in Organic Synthesis" by Greene and Wuts. (third edition) ", and these may be appropriately used depending on the reaction conditions.
- This production process is the compound (la), subjected to cyclization reaction using Chio urea (Step 1), the resulting thiazole 5-position Kishirupiperajino to consequent opening group of the compound (lb) (Step 2), and piperidine carboxylic acid or a protected form thereof is bound to the compound (Id) obtained by amidation reaction of the obtained compound (lc) with dichloromouth nicotinic acid (Step 3).
- This is a method for producing the compound of the present invention by subjecting the compound to a conventional salt formation reaction after deprotection (step 4).
- step 1 after the halogenation of the carbonyl ⁇ -position of the compound (la), typically by the use of a brominating agent such as bromine or N-bromosuccinimide, the cyclization reaction is carried out using thiourea. This is a step of constructing a thiazole ring.
- the halogenating agent used for the halogenation may be any halogenating agent that is generally used for a halogenation reaction at the carbonyl ⁇ -position, and may be any of imides such as ⁇ -bromosuccinimide ⁇ Halogenating agents, pyridines such as dioxane diamide, phenyl trimethy ⁇ / ammonium tribromide, pyridinium hydropromide phenol, pyrrolidone hydrotribromide, ⁇ -pyrrolidone, quaternary ⁇ Perbromides such as ammonium and dioxane are preferably used, but simple halogens such as chlorine and bromine, hydrohalic acids such as hydrogen chloride and hydrogen bromide, copper bromide (I 1), chloride A metal reagent such as copper (II) halide such as copper (II) can also be used.
- imides such as ⁇ -bromosuccinimide ⁇ Halogenating agents
- the reaction is carried out in an organic solvent inert to the reaction of halogenated hydrocarbons, ethers, alcohols, aromatic hydrocarbons, acetic acid, esters, etc., and the reaction temperature is from -30 ° C to the reflux temperature of the solvent used. It is preferred to carry out.
- the thiazole cyclization reaction is carried out in a solvent inert to the reaction, preferably in alcohols such as ethanol and 2-propanol, under cooling, at cooling to room temperature, or at room temperature to heating.
- a solvent inert preferably in alcohols such as ethanol and 2-propanol
- step 2 after halogenation of compound (lb) at the 5-position of thiazole, typically bromination using a brominating agent such as N-bromosuccinimide, a substitution reaction with cyclohexylbiperazine is performed, and In this step, a hexylbiperazino group is introduced.
- the halogenation reaction can be carried out according to the halogenation reaction in step 1, and the replacement reaction is carried out in a solvent inert to the reaction (ethers such as tetrahydrofuran, and N, N-dimethylformamide, N-methylpyrrolidone).
- An aprotic polar solvent such as, for example, is preferably used.
- either compound may be used in excess, or N-methylmorpholine, trimethinoleamine, triethylamine, ⁇ , ⁇ -dimethylaniline, pyridine, 4- ( ⁇ , ⁇ -dimethylamino) pyridine, picoline
- a base such as lutidine
- Step 3 is a step of condensing compound (lc) and dichloronicotinic acid by an amidation reaction
- dichloronicotinic acid may be a reactive derivative thereof.
- reactive derivatives include acid halides such as acid chloride and acid promide. Acid; azide; active ester with N-hydroxybenzotriazole, P-ditrophenol N-hydroxysuccinimide, etc .; symmetric acid anhydride; alkyl carbonate, P-toluenesulfonic acid, etc. And the like.
- acid chloride is generated using a clotting agent such as o ⁇ >), oxychloride phosphorus, oxalic acid chloride, thionyl chloride, etc., and the compound (lc) is allowed to act to condense the condensation. How to do it.
- a clotting agent such as o ⁇ >
- oxychloride phosphorus e.g., oxychloride phosphorus
- oxalic acid chloride e.g., thionyl chloride
- thionyl chloride e.g., thionyl chloride, etc.
- the compound (lc) is allowed to act to condense the condensation. How to do it.
- dichloronicotinic acid is reacted with a free acid, or when the reaction is carried out without isolation of an active ester diacid halide, dicyclohexylcarbodiimide, carbodiimidazole, diphenylphosphoryl azide can
- a condensing agent such as getyl phosphoryl cyanide ⁇ 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride, or phosphorus oxychloride in a pyridine solvent.
- the reaction varies depending on the reactive derivative and the condensing agent used, but is usually stoichiometric hydrocarbons, aromatic hydrocarbons, ethers, esters, acetonitrile, ⁇ , ⁇ -dimethylformamide ⁇ dimethyl sulfoxide, etc.
- the reaction is carried out in an organic solvent inert to the reaction under cooling, from cooling to room temperature, or from room temperature to heating.
- step 4 after substituting the 6-position of the pyridine port of compound (Id) with piperidine carboxylic acid or a protected form thereof, deriving the carboxylic acid as necessary, a salt-forming reaction is performed using maleic acid.
- a salt-forming reaction is performed using maleic acid.
- the substitution reaction with piperidine carboxylic acid or a protected form thereof can be carried out according to the substitution reaction in Step 2, and the necessary derivatization to carboxylic acid and the salt formation reaction are carried out by a method obvious to those skilled in the art or a method similar thereto. The method can be applied.
- the compound of the present invention thus produced is isolated and purified by applying ordinary chemical operations such as extraction, concentration, distillation, crystallization, filtration, recrystallization, and various types of chromatography.
- Industrial applicability such as extraction, concentration, distillation, crystallization, filtration, recrystallization, and various types of chromatography.
- the compound of the present invention has an excellent platelet increasing effect.
- the compound of the present invention is useful for aplastic anemia, thrombocytopenia in myelodysplastic syndrome, thrombocytopenia due to chemotherapy or radiation therapy for malignant tumors, idiopathic thrombocytopenic purpura, thrombocytopenia in liver disease, and HIV-induced It is useful for the treatment and / or prevention of various thrombocytopenia, such as thrombocytopenia. It can also be administered in advance. Further, the compound of the present invention has sufficient oral absorbability when used as an oral preparation.
- Efficacy The maximum cell proliferation activity of the test compound when the maximum cell proliferation activity of rhTPO is defined as 100%.
- Comparative compound 180 111 In the table, the comparative compound is the compound of Example 2 described in Patent Document 9 and has the following structure.
- the medicament of the present invention comprises a compound for use in the present invention, which is usually used for the formulation of the compound of the present invention. It can be prepared by a commonly used method using a excipient and other additives. Administration is oral, such as tablets, pills, capsules, granules, powders, and liquids, injections such as intravenous and intramuscular injections, or non-oral administrations such as suppositories, nasal, transmucosal, and transdermal Either form may be used.
- the compound of the present invention may contain at least one inert diluent such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, aluminate metasilicate. It is mixed with magnesium etc.
- inert diluent such as lactose, mannitol, glucose, hydroxypropylcellulose, microcrystalline cellulose, starch, polyvinylpyrrolidone, aluminate metasilicate. It is mixed with magnesium etc.
- the composition may contain additives other than an inert diluent, for example, a lubricant such as magnesium stearate, a disintegrant such as calcium fiber glycolate, a stabilizer such as lactose, daltamic acid or It may contain a solubilizing agent such as aspartic acid.
- Tablets or pills may be coated with sugar coating such as sucrose, gelatin, hydroxypropylcellulose, hydroxypropylmethylcellulose phthalate or the like, or with a gastric or enteric film, if necessary.
- Liquid compositions for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, elixirs and the like, and commonly used inert diluents such as purified water Contains ethanol (EtOH).
- the composition may contain, in addition to the inert diluent, adjuvants such as wetting agents and suspending agents, sweetening agents, flavoring agents, fragrances, and preservatives.
- Injections for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions.
- Aqueous solutions and suspensions include, for example, distilled water for injection and physiological saline.
- Non-aqueous solutions and suspensions include, for example, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, alcohols such as EtOH, polysorbate 80 and the like.
- Such compositions are furthermore preservative Agents, wetting agents, emulsifying agents, dispersing agents, for example, stabilizers such as ratatose, and adjuvants such as dissolution aids such as dispartic dalpartate.
- the daily dose is about 0.0001 to 50 mg / kg per body weight, preferably about 0.001 to 10 mg / kg, and more preferably 0.01 to 1 mg / kg. It is administered once or in 2 to 4 divided doses.
- the daily dose is about 0.0001 to 1 mg / kg, preferably about 0.0001 to 0.1 mg / kg per body weight, and is administered once to several times a day. The dose is appropriately determined depending on the individual case in consideration of symptoms, age, sex, and the like.
- the starting compounds used in the examples also include novel substances, and a method for producing such starting compounds from known substances will be described as reference examples.
- FIG. 1 Thermogravimetric analysis data of the compound of Example 1 c
Abstract
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004539569A JP4317818B2 (ja) | 2002-09-30 | 2003-09-29 | 2−アシルアミノチアゾール誘導体の新規な塩 |
AU2003268687A AU2003268687A1 (en) | 2002-09-30 | 2003-09-29 | Novel salt of 2-acylaminothiazole derivative |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002284689 | 2002-09-30 | ||
JP2002-284689 | 2002-09-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004029049A1 true WO2004029049A1 (ja) | 2004-04-08 |
Family
ID=32040589
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/012419 WO2004029049A1 (ja) | 2002-09-30 | 2003-09-29 | 2-アシルアミノチアゾール誘導体の新規な塩 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP4317818B2 (ja) |
AU (1) | AU2003268687A1 (ja) |
WO (1) | WO2004029049A1 (ja) |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006219481A (ja) * | 2005-01-12 | 2006-08-24 | Astellas Pharma Inc | アシルアミノチアゾール誘導体の製造法 |
WO2008073864A1 (en) * | 2006-12-12 | 2008-06-19 | Smithkline Beecham Corporation | Novel combinations |
WO2007054783A3 (en) * | 2005-11-08 | 2008-07-03 | Astellas Pharma Inc | Compositions and methods for treating thrombocytopenia |
WO2008101141A2 (en) | 2007-02-16 | 2008-08-21 | Smithkline Beecham Corporation | Cancer treatment method |
WO2008021283A3 (en) * | 2006-08-08 | 2008-12-11 | Akarx Inc | Compositions and methods for increasing blood platelet levels in humans |
WO2009017098A1 (ja) | 2007-07-31 | 2009-02-05 | Shionogi & Co., Ltd. | トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物を含有する医薬組成物およびその中間体 |
US7638536B2 (en) | 2002-01-18 | 2009-12-29 | Astellas Pharma Inc. | 2-Acylaminothiazole derivative or salt thereof |
JP2010516668A (ja) * | 2007-01-17 | 2010-05-20 | エルジー ライフ サイエンス リミテッド | 抗ウイルス剤のマレイン酸モノ塩及びそれを含有する医薬組成物 |
WO2013018362A1 (en) | 2011-08-03 | 2013-02-07 | Astellas Pharma Inc. | 2-acylaminothiazole compound crystals |
US8609693B2 (en) | 2009-05-29 | 2013-12-17 | Glaxosmithkline Llc | Methods of administration of thrombopoietin agonist compounds |
CN106749226A (zh) * | 2017-03-15 | 2017-05-31 | 广东赛拓医药科技有限公司 | 一种avatrombopag马来酸盐晶型C的制备方法 |
CN107383000A (zh) * | 2017-08-07 | 2017-11-24 | 瑞阳制药有限公司 | 血小板增多剂的制备方法 |
WO2020044364A1 (en) | 2018-08-27 | 2020-03-05 | Mylan Laboratories Limited | Polymorphic forms of avatrombopag maleate |
CN112409350A (zh) * | 2020-11-27 | 2021-02-26 | 上海迪赛诺生物医药有限公司 | 一种马来酸阿伐曲泊帕晶型c的制备方法 |
CN112480106A (zh) * | 2020-11-17 | 2021-03-12 | 南京海纳医药科技股份有限公司 | 一种马来酸阿伐曲泊帕杂质的制备方法 |
CN115057854A (zh) * | 2022-04-19 | 2022-09-16 | 河北常山生化药业股份有限公司 | 马来酸阿伐曲泊帕中间体的制备方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8476249B2 (en) | 2009-05-07 | 2013-07-02 | Glaxosmithkline Llc | Method of treating thrombocytopenia |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002062775A1 (fr) * | 2001-02-02 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | Dérivé de 2-acylaminothiazole ou son sel |
WO2003062233A1 (fr) * | 2002-01-18 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de 2-acylaminothiazole et son sel |
-
2003
- 2003-09-29 JP JP2004539569A patent/JP4317818B2/ja not_active Expired - Lifetime
- 2003-09-29 WO PCT/JP2003/012419 patent/WO2004029049A1/ja active Application Filing
- 2003-09-29 AU AU2003268687A patent/AU2003268687A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002062775A1 (fr) * | 2001-02-02 | 2002-08-15 | Yamanouchi Pharmaceutical Co., Ltd. | Dérivé de 2-acylaminothiazole ou son sel |
WO2003062233A1 (fr) * | 2002-01-18 | 2003-07-31 | Yamanouchi Pharmaceutical Co., Ltd. | Derive de 2-acylaminothiazole et son sel |
Cited By (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765764B2 (en) | 2002-01-18 | 2014-07-01 | Astellas Pharma, Inc. | 2-acylaminothiazole derivative or salt thereof |
US8338429B2 (en) | 2002-01-18 | 2012-12-25 | Astellas Pharma, Inc. | 2-acylaminothiazole derivative or salt thereof |
US7638536B2 (en) | 2002-01-18 | 2009-12-29 | Astellas Pharma Inc. | 2-Acylaminothiazole derivative or salt thereof |
JP2006219481A (ja) * | 2005-01-12 | 2006-08-24 | Astellas Pharma Inc | アシルアミノチアゾール誘導体の製造法 |
JP4665769B2 (ja) * | 2005-01-12 | 2011-04-06 | アステラス製薬株式会社 | アシルアミノチアゾール誘導体の製造法 |
AU2006313491B2 (en) * | 2005-11-08 | 2011-01-06 | Astellas Pharma Inc. | Compositions and methods for treating thrombocytopenia |
WO2007054783A3 (en) * | 2005-11-08 | 2008-07-03 | Astellas Pharma Inc | Compositions and methods for treating thrombocytopenia |
JP2009514941A (ja) * | 2005-11-08 | 2009-04-09 | アステラス製薬株式会社 | 血小板減少症を治療する化合物および方法 |
WO2008021283A3 (en) * | 2006-08-08 | 2008-12-11 | Akarx Inc | Compositions and methods for increasing blood platelet levels in humans |
JP2015221806A (ja) * | 2006-08-08 | 2015-12-10 | アカークス,インコーポレーテッド | ヒトの血小板レベルを増加させるための組成物および方法 |
JP2010500361A (ja) * | 2006-08-08 | 2010-01-07 | アカークス,インコーポレーテッド | ヒトの血小板レベルを増加させるための組成物および方法 |
AU2011253775B2 (en) * | 2006-08-08 | 2014-02-13 | Akarx, Inc. | Compositions and Methods for Increasing Blood Platelet Levels in Humans |
AU2007284644B2 (en) * | 2006-08-08 | 2011-09-01 | Akarx, Inc. | Compositions and methods for increasing blood platelet levels in humans |
EP2452674A2 (en) | 2006-08-08 | 2012-05-16 | Akarx, Inc. | Compositions and methods for increasing blood platelet levels in humans |
JP2013047257A (ja) * | 2006-08-08 | 2013-03-07 | Akarx Inc | ヒトの血小板レベルを増加させるための組成物および方法 |
WO2008073864A1 (en) * | 2006-12-12 | 2008-06-19 | Smithkline Beecham Corporation | Novel combinations |
JP2010516668A (ja) * | 2007-01-17 | 2010-05-20 | エルジー ライフ サイエンス リミテッド | 抗ウイルス剤のマレイン酸モノ塩及びそれを含有する医薬組成物 |
JP2010519221A (ja) * | 2007-02-16 | 2010-06-03 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 癌の治療方法 |
WO2008101141A2 (en) | 2007-02-16 | 2008-08-21 | Smithkline Beecham Corporation | Cancer treatment method |
US8530668B2 (en) | 2007-07-31 | 2013-09-10 | Shionogi & Co., Ltd. | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
WO2009017098A1 (ja) | 2007-07-31 | 2009-02-05 | Shionogi & Co., Ltd. | トロンボポエチン受容体アゴニスト作用を有する光学活性な化合物を含有する医薬組成物およびその中間体 |
US8889722B2 (en) | 2007-07-31 | 2014-11-18 | Shionogi & Co., Ltd. | Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor |
US8609693B2 (en) | 2009-05-29 | 2013-12-17 | Glaxosmithkline Llc | Methods of administration of thrombopoietin agonist compounds |
WO2013018362A1 (en) | 2011-08-03 | 2013-02-07 | Astellas Pharma Inc. | 2-acylaminothiazole compound crystals |
EP3246325A1 (en) | 2011-08-03 | 2017-11-22 | Astellas Pharma Inc. | 2-acylaminothiazole compound crystals |
CN106749226A (zh) * | 2017-03-15 | 2017-05-31 | 广东赛拓医药科技有限公司 | 一种avatrombopag马来酸盐晶型C的制备方法 |
CN107383000A (zh) * | 2017-08-07 | 2017-11-24 | 瑞阳制药有限公司 | 血小板增多剂的制备方法 |
WO2020044364A1 (en) | 2018-08-27 | 2020-03-05 | Mylan Laboratories Limited | Polymorphic forms of avatrombopag maleate |
CN112480106A (zh) * | 2020-11-17 | 2021-03-12 | 南京海纳医药科技股份有限公司 | 一种马来酸阿伐曲泊帕杂质的制备方法 |
CN112409350A (zh) * | 2020-11-27 | 2021-02-26 | 上海迪赛诺生物医药有限公司 | 一种马来酸阿伐曲泊帕晶型c的制备方法 |
CN112409350B (zh) * | 2020-11-27 | 2023-12-19 | 上海迪赛诺生物医药有限公司 | 一种马来酸阿伐曲泊帕晶型c的制备方法 |
CN115057854A (zh) * | 2022-04-19 | 2022-09-16 | 河北常山生化药业股份有限公司 | 马来酸阿伐曲泊帕中间体的制备方法 |
Also Published As
Publication number | Publication date |
---|---|
AU2003268687A1 (en) | 2004-04-19 |
JP4317818B2 (ja) | 2009-08-19 |
JPWO2004029049A1 (ja) | 2006-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10710987B2 (en) | Hydrochloride salt form for EZH2 inhibition | |
JP6938561B2 (ja) | 重水素化2,4−チアゾリジンジオン及び治療方法 | |
WO2004029049A1 (ja) | 2-アシルアミノチアゾール誘導体の新規な塩 | |
JP5283336B2 (ja) | 選択的キナーゼ阻害剤 | |
JP2020500207A (ja) | カルパインモジュレーター及びそれらの治療上の使用 | |
TW201639828A (zh) | 4h-吡咯[3,2-c]吡啶-4-酮衍生物 | |
CN110036005A (zh) | 酰胺衍生物及其在药物中的应用 | |
TWI481604B (zh) | Novel 5-fluorouracil derivatives | |
WO2018177403A1 (zh) | 1H-咪唑[4,5-h]喹唑啉类化合物作为蛋白激酶抑制剂 | |
WO2003062233A1 (fr) | Derive de 2-acylaminothiazole et son sel | |
JPWO2002062775A1 (ja) | 2−アシルアミノチアゾール誘導体又はその塩 | |
OA13235A (en) | Piperazine derivatives for the treatment of HIV infections. | |
EA021025B1 (ru) | Соединения, эффективные в качестве ингибиторов ксантиноксидазы, способ их получения и содержащая их фармацевтическая композиция | |
BG102948A (bg) | Пиразинони като инхибитори на тромбин | |
US20160024047A1 (en) | Multisubstituted aromatic compounds as serine protease inhibitors | |
TW200904440A (en) | Method for modulating GPR119 G protein-coupled receptor and selected compounds | |
KR20120016674A (ko) | 트리아진 유도체와 이들의 치료적 용도 | |
EP2665709A1 (en) | Diarylacetylene hydrazide containing tyrosine kinase inhibitors | |
CN101384586A (zh) | Pi-3激酶抑制剂及其应用方法 | |
WO2012155806A1 (zh) | 4-氨基喹唑啉衍生物及其应用 | |
US9975906B2 (en) | Tricyclic heterocycle derivatives having HIV replication inhibitory effect | |
CN110724139A (zh) | 用于抑制蛋白激酶活性的(杂)芳基酰胺类化合物 | |
WO2004035579A1 (ja) | イミダゾピリジン誘導体、その製造法および用途 | |
WO2002030920A1 (fr) | Composes derives de benzimidazole, leur procede de production et leur utilisation | |
CN104797573A (zh) | 新的组蛋白脱乙酰基酶抑制剂及其在治疗中的用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004539569 Country of ref document: JP |
|
122 | Ep: pct application non-entry in european phase |